Theory

FOUR-PARAMETER LOGISTIC EQUATION
Let X denote a concentration of analyte and let Y be the response measured from assaying the analyte sample. We let [IIX,O] denote the error probability density of the response V given analyte concentration X, where 0 is the vector of parameters that defines the specific form of the probability density. The error probability density summarizes all uncertainty in the response for a given analyte concentration; its mean function, E (YIX, 0) , is the assay dose-response curve; and its variance function, V(}IXO), describes the variance of the response for a given analyte concentration and level of experimental error [9J. [12] [13] [14] . Each gives a different prescription for the optimal reagent combination and prediction of the MDC that combination should yield [12] [13] [14] . In the analysis of immunoassay data, the more common practice is to represent the dose-response curve with the empirically derived 4PL equation (Eq. 1) instead of a mass-action law approximation. With respect to the 4PL equation, the Yalow-Berson and Ekins-Newman definitions are respectively: 0 and undefined if #{176}2 = 0 or 1021 >1; both finite in the special case of 1021= 1; and negative infinity and undefined if 1021 <1. Thus, MDC estimates based on these definitions cannot be reported as part of routine laboratory analyses.
Currie proposed three definitions of the MDC (Table 1) for calibrated analytic methods: the critical limits (X. or Xe.), the detection limit (Xi), and the determination limit (Xq) [15] . The critical limit X. estimates an upper 1-a confidence bound of the blank calibrator or zero dose computed from V()IX,0). The empirical critical limit X.. estimates an upper 0.975 confidence bound, i.e., upper bound of the 0.95 confidence interval of the zero dose, computed from s, the sample standard deviation of the blank responses. The critical limit sets a cutoff at which it can be concluded that an analyte has been detected. X is the analyte concentration that has X. as its 1-p lower confidence bound. X, defines a concentration at which the analyte may be reported as reliably detected, where reliably detected means with probability 1-f3. Xq is the smallest analyte estimate that can be measured quantitatively with a specified level of precision, where the acceptable level of precision is defined as a coefficient of variation (CV). Currie's definitions separate the neighborhood near the zero dose into three analytic regions: the regions of (a) unreliable detection, is defined by the 1-a quantile of the probability density of the zero dose. We show below that the EkinsNewman and the critical limit definitions have different probabilities of type I error because they estimate different quantiles of the zero dose probability density by using different approximation methods. The type II error of level (3 (probability of a nonzero dose being declared as zero) is defined in terms of the probability density of an analyte concentration near the zero dose whose f3 quantile is the critical limit. The mean of this probability density is the detection limit. incorrectly as a synonym of the MDC [22, 23] . Hence, this definitheorem is a basic law of elementary probability theory used to tion will not be used in formulating our definition of the MDC compute the probability of one event, given that another has or in our data analyses. occurred. This law is especially appropriate for immunoassay
There are six important shortcomings in the formulation and use of Currie's definitions as applied to immunoassays. First, the critical limit definition considers only the type I error, i.e., the error in the zero dose or blank calibrators.
Second, neither the analyses in which, given a specimen's response, we wish to infer what is the most probable analyte concentration the specimen contains. Bayes' theorem can be used to give a mathematical formulation of this statement in terms of a posterior probability critical limit nor the detection limit provides a measure of precision for its MDC estimate, whereas the determination limit density [26] . If [X1Y,01 denotes the posterior probability density of X given Y, then by Bayes' theorem does not provide a measure of either type I or type II error [24] .
Third, each definition assumes implicitly that the uncertainty in low analyte concentrations can be approximated by symmetric probability densities such as the gaussian or t. Because negative analyte values are not possible, the probability density of an analyte concentration near zero must be skewed to the right (see Fig. 1A below). Fourth, the critical limit is the most commonly used MDC definition primarily because the empirical critical limit is the simplest to compute. It appears to be forgotten that Currie placed the critical limit well within his region of unreliable detection and that he considered the detection limit to be the smallest analyte concentration that may be reported as detected reliably. As stated above, the detection limit is the border between the regions of unreliable detection and detection acceptable for qualitative analysis. Fifth, backfltting, inverting the dose-response curve formula in Eq. 1 to compute X for a given Y, is the method used in these three definitions to estimate the analyte for a given response. Although backfitting gives reasonable analyte estimates, the associated error estimates derived from this technique can be less reliable [25] . The prior probability density represents the range of analyte concentrations likely to be observed in the assay and is defined primarily by the assay's working range [16] .An immunoassay is by design a statistically informative experiment in that, for any specimen containing an unknown concentration of analyte, information from the assay analysis dominates that known before performing the assay. Therefore,
[X] can be modeled as a uniform probability density [27] . We have determined from empirical study of numerous . immunoassay systems that [X] is well described by a uniform probability density on the interval from 0 to 1.5 times the largest nonblank calibrator [28] . Defining explicit functional forms for the prior and error probability densities is essential to apply Bayes' theorem in immunoassay data analyses. Given V, the response of a specimen containing an unknown concentration of analyte, Bayes' theorem combines information about the immunoassay's properties summarized in the prior probability density with information from the assay experiment defined by [YIX,O} to compute the most probable set of analyte concentrations for that response. The set of analyte concentrations over which the posterior probability density [X]Y,0] takes lues defines the uncertainty in the analyte for that on nonzero va response.
In other words, the posterior probability density summarizes all the uncertainty concerning the concentration of analyte in a specimen once the response of that specimen has been measured. To report immunoassay findings, it is necessary to choose a single representative concentration from the set defined by [X1Y,0I to be the analyte estimate for the response.
tration. Assay laboratories often address this ambiguity by setting a conservative lower reporting limit well above the MDC We use the median instead of the mean as the analyte estimate for each posterior probability density because the median prostated by the assay's manufacturer.
vides a more representative single number summary for a
DEFINITION OF MDC BASED ON BAYES' THEOREM
skewed probability density. The two are equal for a symmetric probability density [29] . 
Brown et a!.: Defining immunoassay minimal detectable concentration either standard least-squares or maximum likelihood methods [9, 28] .
We interpret the statement that the MDC is the smallest analyte concentration an immunoassay can reliably measure to mean the smallest analyte concentration that may be reported to be greater than the assay's zero dose with a high probability, say 0.95. We take the zero dose to be the set of analyte concentrations that may be inferred from the response of the blank calibrators and represent it explicitly in terms of a posterior probability density with Eq 2. With this interpretation we can use Bayes' theorem to formulate a definition of the MDC in terms of the probability density of the zero dose and the probability densities of concentrations near the zero dose. In this way, we extend the concept of type I error to the consideration of all the uncertainty in the zero dose and we extend the concept of type II error to consideration of all the uncertainty in any analyte concentration near the zero dose. We can also define the precision with which the MDC is determined both as the probability that it exceeds the zero dose atid as the CV of its probability density. Therefore, we arrive at one definition that considers all the concepts in the four MDC definitions.
The formal statement of our definition is as follows. 
where X,ssax is the upper endpoint of the range of the prior density. As stated above, x,5, is taken to be 1.5 times the largest nonblank calibrator.
The lower limit of 0.5 for p follows from Lemma I in the Appendix.
To understand this definition of the MDC, we describe its logic with the aid of a graphical representation in Fig. 1 . First, we set p equal to an acceptable level of certainty such as 0.95. Once Y0, the responses of the blank calibratbrs, have been measured and the assay dose-response relation defined by Eq. 1 has been estimated by using the calibrators and their responses, we may use Eq. 2 to compute the posterior probability density [X1Y,0] (broken curve in Fig. 1A ). This probability density defines the error in the zero dose, i.e., the set of concentrations that is most likely, given the responses of the blank calibrators. This probability density illustrates the extent to which the uncertainty in the blank calibrators extends into nonzero concentrations.
As mentioned above, it is necessarily skewed to the Fig. 1A ) as the associated analyte estimate for that response. To compute our definition of the MDC, we must compute the probability that an analyte estimate is greater than the zero dose. This probability is the same as the probability that the difference between the analyte estimate and zero dose is greater than zero. The probability density [XIV, 0] (Fig. IB) Table 1 . The detection limit, Xe,, is a largesample approximation to X,, since it finds the analyte concentration that is greater than the zero dose with probability l-/3. The zero dose is estimated by X., an approximation of the 1-a quantile of the zero dose probability density. The formula for the detection limit in Table 1 uses backfitting and a t-density approximation to estimate both X. and the mean of the probability density that has X. as its /3 quantile.
Kb, in contrast, is computed by comparing the probability density of the zero dose with the probability density of every analyte concentration near the zero dose. Moreover, Xb can be computed for any choice of
. In Proposition 4 we show that X may be derived as a special case of X,,.
The concept of precision used in the definition of is an explicit property of Xh. This is because each posterior probability density defined by Eq. 2 for [X], a uniform probability density, and [Y1X,0], a gaussian probability density, has a well-defined CV. More generally, because Kb has an associated probability density, its precision may be stated in terms of the probability that it is greater than the zero dose, its CV, or any other property of its probability density that may be analytically important.
In Proposition 5 we show that if y is given and Eq. 2 is used in lieu of the gaussian approximation of Table I to compute X0, then it is possible to find p in Definition 1 such that X5 = Xh. Conversely we show that, given p, it is possible to find y such that Xb = Xq Therefore, if a certain level of measurement precision is given in terms of an immunoassay CV, then the probability that the analyte concentration associated with that CV is greater than the zero dose can be determined. On the other hand, if we know how sure we must be to conclude that a concentration is greater than the zero dose, then for the analyte concentration associated with that level of certainty, we can find its precision in terms of its CV.
In Proposition 6 we show that both the probability of a measurement from [X]V0,0] being misclassified as greater than the MDC and the probability of a measurement from the probability density of the MDC being misclassified as indistinguishable from the zero dose equal l-p.
Materials and Methods
THE ABBOTT MEIA FOR PSA
To investigate the implications of our definition, we studied the Abbott MEIA for PSA [31] .Serum PSA concentrations are measured to screen for prostate cancer and to monitor its recurrence after medical or surgical therapy [32, 33] . The American Cancer Society recently recommended annual screening [IIX,0j was the gaussian density defined in Eq. 1. Since the largest nonblank calibrator was 100 j.g/L, we took [X] to be the uniform density on [0, 150] as discussed in Theory. The parameter 0 was estimated by maximum likelihood in each repetition of the experiment from the complete set of 40 observations [28] .
The blank calibrators were made from sera of normal, healthy women blood donors. Because the IiMx analyzer can accommodate only 24 specimens, each run was performed in two parts by using the analyzer's mode one calibration between parts. Four MDC analyses denoted F through I were performed on the data from each repetition of the experiment (Table 2 ). In each analysis X., X.., Xd, and were computed from the formulae in Table 1 
Results
The same relations among the MDC estimates
held in each repetition of the experiment (Fig. 2) . In all analyses X,, was less than the conservative estimates of Xi., X, and Xq, yet greater than the optimistic estimates of Xe.. Xi.. agreed most closely with reported MDC values, ranging from 0.02 1 to 0.076 .tg/L (median 0.059 .tg/L). It did not approach the 0.95 quantile of [X1V,0] until the number of blank replicates was 20, mainly because the latter probability densities were all right-skewed (Fig. 3 )5 X,, is 1.6-2.3 times greater than the 0.95 quantile of [X1Y,0] in the third repetition of the assay experiment, indicating that, even when well characterized, the latter appreciably underestimates the MDC (Fig. 3 and Table 3 ). The percent CVs for the zero doses in Fig. 3 These latter observations are not surprising, since Proposition I shows that, even when the same values of a are used in both definitions of the critical limit, X. will tend to be larger because of the prediction error variance term in its formula. Similarly, Proposition 4 shows that X is typically larger than X,,.
In each repetition of the experiment, X1, decreased the most between analyses F and G (Figs. 2 and 3 ). With 20 blank replicates, increasing the number of specimen replicates from two to four produced only a marginal decrease in X1,. As the number of calibrators increased, the X0 probability densities became more right-skewed (Fig. 3) . [39] . The greater-thanfourfold median ratio we found between X,, in the routine assays and X. in the calibration assays together with the high interassay correlations found in these studies raises the possibility that a ratio of similar magnitude may exist in these three PSA assays. Two other specially designed PSA assays have reported MDCs based on Xi.. of 0.009 and 0.03 g/L, computed with respectively 20 and 12 replicates of the blank calibrator [40, 41] . Our analysis suggests that these MDC estimates may be understated because of the shortcomings in the definition of Xi..
coupled with the fact that in routine use of the assay it is unlikely that as many blank calibrators would be used. Fig. 2 formulates the MDC definition explicitly in terms of the probability that an analyte is greater than the blank calibrators. The second obviates the need to combine backfitting and t-density or gaussian approximations to right-skewed probability densities to treat simultaneously the error in the blank calibrators and in analyte concentrations to the right of zero. These improvements are primarily responsible for the differences we found between the current MDC definitions and Xh, and why the latter is a more reliable MDC measure determined with either a small or large number of specimen replicates.
X its MDC as <600 molecules [43] . Our paradigm offers a rigorous means of quantifying improvements in assay MDCs.
The high specificity of monoclonal antibodies and sandwich assays suggests that for certain immunoassays the accuracy of our methods can be enhanced by deriving the dose-response curve from the mass-action laws. Improvements may also be made by developing a more physically based probability model of the assay experimental error and by taking account of interassay variation. To account for interassay variation in the definition of Xb, we can define the probability densities
where -s indicates convergence in probability [44] .Similarly,
as k-scc and therefore, 
Also as k-#{247}x, the t-density converges to a standard gaussian probability density and in particular, with t -#{176} = t979, the 0.975th quantile of the t-density converges to 1.96=2, the 0.975th quantile of a standard gaussian density /45J. Combining these results with the definitions of X. and X.. in Table 1 shows that when k is large, both X. and Xj.. are defined by
The numerical differences If the parameters of the dose-response curve are known, then for a given dose X0, the 95% confidence interval for the mean response is random variable A'7, in Definition I is fixed at its 1-a quantile, then X, = X,,.
Proof: Expressed in terms of posterior probability densities, A is
and Xd is the mean of the probability density that satisfies the
(A.9)
From DefInition 1, A',, is the median of the probability density [X1Y,01, which satisfies the condition 
By Eq. A.8, A',. = x1_,,. The probability density of A',, is approximately symmetric, so that its median and its mean are approximately equal. It follows that Eq. A.9 and Eq. A.l2 agree anti thatX', = A',, with p = 1-p.
Because X,,considers the entire probability density of the zero dose, whereas X, estimates the zero dose by its 1-a quantile, X, will tend to be larger than A',,.
Lemma 1. If X is the random variable associated with [XJY,#{128})]
and A'7, is as given in Definition I, then 0. in Eq. A.6 is also used in the determnination limit definition in 
PROPOSITION
6
The probability of a measurement from [Al Y0,01 being misclassified as greater than the zero dose is i-p. Similarly, the probability of a measurement from the probability density of the MDC being misclassified as indistinguishable from the zero dose is i-p. Proof.
A measurement from [XlY,0] is misclassified as greater than the zero dose if X7,, >X7, where X7 is the random variable associated with the probability density of the MDC. By Definition 1,the probability of this event is Pr(X7,, >X) = 1 -Pr(X7,, X7) = I -Pr(X7,,<A'7) = 1 -p, since A' is a continuous random variable. A measurement from the probability density of the MDC is misclassified as indistinguishable from the zero dose if X7 X7,,.
The probability of this event is Pr(X7X7,) = 1-Pr(X7>A'7,,) = i-p.
